About 200 reports

OVERALL, ##% AND ##% OF PATIENTS WITH AML REQUIRED DOSE ADJUSTMENT DUE TO GASTROINTESTINAL OR HEMATOLOGIC AES, RESPECTIVELY (SAVONA ET AL., 2014).

  • Leukemia
  • Astellas Pharma Inc.
  • Astex Pharmaceuticals, Inc.
  • Celgene Corporation
  • Novartis AG
  • HEMATOLOGICAL CANCERS THERAPEUTICS MARKET, GLOBAL, APPROVED INDICATIONS FOR
  • HEMATOLOGICAL CANCERS THERAPEUTICS MARKET, GLOBAL, APPROVED INDICATIONS FOR

It is also in development within the gastrointestinal disease area.

  • Leukemia
  • World
  • Market Size
  • Celgene Corporation
  • Novartis AG

gastrointestinal, central nervous system, and hormonal therapies).

  • Leukemia
  • Alcon, Inc.
  • Amgen Inc.
  • Bristol-Myers Squibb Company
  • Novartis AG
  • Leukemia
  • AbbVie Inc.
  • Amgen Inc.
  • Biogen Idec Inc.
  • Bristol-Myers Squibb Company

It is used in treating chronic myelogenous leukemia (CML), gastrointestinal stromal tumors (GISTs) and a number of other malignancies.

  • Leukemia
  • China
  • Trade
  • Lijun Pharmaceutical Co., Ltd.
  • Shanghai Schering-Plough Pharmaceutical Company, Ltd

It is used in treating chronic myelogenous leukemia (CML), gastrointestinal stromal tumors (GISTs) and a number of other malignancies.

  • Leukemia
  • China
  • Demand
  • Market Size
  • Shanghai Schering-Plough Pharmaceutical Company, Ltd

They have sixty plus products on market, covering categories of gastrointestinal, cardiovascular, anti-tumor, and antibiotics. - Haitian International Trading Co., Ltd.

  • Leukemia
  • China
  • Supply
  • Zhejiang Expressway Co., Ltd.
  • Zhejiang Hisun Pharmaceutical Co., Ltd.
  • GLEEVEC DRUG PROFILE
  • Leukemia
  • Amgen Inc.
  • ARIAD Pharmaceuticals, Inc.
  • Novartis AG
  • Pfizer Inc.
  • GASTROINTESTINAL STROMAL TUMOR (GIST) - PIPELINE BY OMEROS CORP, H1 2017
  • GASTROINTESTINAL STROMAL TUMOR (GIST) - PIPELINE BY NATCO PHARMA LTD, H1 2017
  • Cancer
  • Leukemia
  • Pharmaceutical
  • United States
  • Product Initiative
  • 1ZIABC0 06198-26
  • 1ZIABC0 11564-01

IN ADDITION, THE STUDY SHOWED THIS ADC HAS MANAGEABLE NEUTROPENIA AND GASTROINTESTINAL TOXICITIES.

  • Leukemia
  • Demand
  • Market Size
  • AbbVie Inc.
  • Seattle Genetics, Inc.

FRONTIER PHARMA First-in-Class Innovation in Hematological Cancers - Cytokine Signaling and Kinase Targeted Immunotherapies Dominate a Large and Highly Versatile Pipeline Published: May 2017 Report Code: GBIHC##MR www. gbiresearch. com © GBI Research.

  • Leukemia
  • World
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • Novartis AG
  • MERCK & CO., INC.
  • June 12, 2015

FINDINGS: May ##, 2015 ## Among these subgroup of subjects, more common grade ## or higher non-hematologic adverse events in the vosaroxin combination arm include gastrointestinal and myelosuppression-related toxicities, consistent with those observed in previous company studies.

  • Blood Disease
  • Clinical Trial
  • Leukemia
  • United States
  • World

They have sixty plus products on market, covering categories of gastrointestinal, cardiovascular, anti-tumor, and antibiotics. - Haitian International Trading Co., Ltd.

  • Leukemia
  • China
  • Nanjing Aosaikang Medicinal Group
  • Zhejiang Expressway Co., Ltd.
  • Zhejiang Hisun Pharmaceutical Co., Ltd.
  • PRESS RELEASE 4

Most common adverse events were grade ##-## and gastrointestinal in nature.

  • Leukemia
  • Japan
  • Demand
  • Celgene Corporation
  • Nippon Shinyaku Co., Ltd.

OTHER PRODUCTS ARE IN DEVELOPMENT IN RESPIRATORY CONDITIONS, BACTERIAL INFECTIONS, CNS/ PAIN, AND GASTROINTESTINAL DYSFUNCTION.

  • Leukemia
  • AstraZeneca PLC
  • Novartis AG
  • Pfizer Inc.
  • Roche Group

The most common co-morbidities in these patients were: gastrointestinal (##-##%) musculoskeletal (##-##%) cardiovascular (##-##%) respiratory (##-##%) dermatologic (##%) hepatobiliary (##-##%) hyperlipidemia (##-##%) diabetes mellitus (##-##%) renal (##-##%). endocrine-metabolic (excluding diabete

  • Leukemia
  • Europe
  • ARIAD Pharmaceuticals, Inc.
  • Novartis AG
  • Pfizer Inc.

The most frequent AEs reported in the AML patients were gastrointestinal; diarrhea and nausea were observed in five out of the nine AML patients (##%).

  • Leukemia
  • Astellas Pharma Inc.
  • Celator Pharmaceuticals, Inc.
  • Celgene Corporation
  • Novartis AG

THE MOST FREQUENT ADVERSE EVENTS REPORTED WERE ASTHENIA AND GASTROINTESTINAL DISORDERS. ## PERCENT (EIGHT OUT OF ## PATIENTS) SHOWED AN OBJECTIVE RESPONSE INCLUDING THREE WHO SHOWED COMPLETE REMISSION.

  • Leukemia
  • United States
  • Amgen Inc.
  • MedImmune, LLC
  • Novartis AG

THE MAIN TARGET INDICATIONS INCLUDE OVARIAN, BREAST, LUNG AND GASTROINTESTINAL TUMORS.

  • Leukemia
  • New Caledonia
  • MedImmune, LLC
  • Roche Group
  • Xencor, Inc.
  • Sareum Holdings Plc - Pipeline by Indication, 2016

Key Facts Sareum Holdings Plc, Key Facts Key Therapeutic Areas Sareum Holdings Plc - Research and Development Overview Sareum Holdings Plc has promising clinical drug candidates for ## major therapeutic areas, Central Nervous System, Gastrointestinal, Oncology and Immunology.

  • Cancer
  • Leukemia
  • Pathology
  • World
  • Sareum Holdings plc
  • Clinical Trial profile. 159 Trial Title
  • Clinical Trial profile. 45 Trial Title

Proportion of Oral Mucositis to Gastrointestinal Clinical Trials, E## Countries (%), 2016* In total there were ## clinical trials conducted on Oral Mucositis, as of September 2016 in E## Countries, of these ## clinical trials were in India.

  • Hospital
  • Leukemia
  • World
  • Product Initiative
  • Amgen Inc.
  • Clinical Trial profile. 18 Trial Title
  • Clinical Trial profile. 32 Trial Title

Proportion of Systemic Mastocytosis to Gastrointestinal Clinical Trials, E## Countries (%), 2015* Proportion of Systemic Mastocytosis to Gastrointestinal Clinical Trials, E## Countries (%), 2015* Proportion of Systemic Mastocytosis to Gastrointestinal Clinical Trials, E## Cou

  • Healthcare
  • Leukemia
  • World
  • Product Initiative
  • Novartis AG
  • Tasigna: Orphan Drug Designation

GASTROINTESTINAL STROMAL TUMOR (GIST) - SECOND LINE* *The study has currently suspended participant recruitment following the temporary suspension of Iclusig in the US market.

  • Leukemia
  • United States
  • ARIAD Pharmaceuticals, Inc.
  • Novartis AG
  • Pfizer Inc.
  • Products under Development by Companies, H2 2017
  • Global Markets Direct Report Coverage

Pts on BOS had significantly higher rates of ##-mo MMR and CCyR and achieved responses faster than those on IM, and had higher incidence of gastrointestinal events and transaminase elevations.

  • Cancer
  • Leukemia
  • Targeted Therapy
  • Therapy
  • Pfizer Inc.
  • selected advanced gastrointestinal and genitourinary tumors. The trial was registered with the U.S. National Institutes of Health.
  • REFRACTORY ACUTE MYELOID LEUKEMIA - PIPELINE BY AROG PHARMACEUTICALS, INC., H1 2016
  • Leukemia
  • Pharmaceutical
  • United States
  • Company
  • Product Initiative
  • PIPELINE BY CHIPSCREEN BIOSCIENCES LTD, H2 2017
  • PRODUCTS UNDER DEVELOPMENT BY COMPANIES, H2 2017

Gastrointestinal Stromal Tumor (GIST), Glioblastoma Multiforme (GBM), Hepatocellular Carcinoma, Kidney Cancer (Renal Cell Cancer), Lung Cancer, Metastatic Breast Cancer, Non-Hodgkin Lymphoma, Peripheral T- Cell Lymphomas (PTCL), Peritoneal Cancer, Prostate Cancer, Refractory Acute Myeloid L

  • Leukemia
  • United States
  • World
  • Product Initiative
  • Sareum Holdings plc
  • Leukemia)
  • GLOBAL MARKETS DIRECT REPORT COVERAGE

One patient had a Sprycel-related AE leading to discontinuation, and one patient died from gastrointestinal bleeding unrelated to treatment.

  • Cancer
  • Leukemia
  • United States
  • Product Initiative
  • AB Science SA
  • TIVANTINIB
  • BREAST CANCER

The data were presented at the 2016 Gastrointestinal Cancers Symposium (ASCO GI).

  • Cancer
  • Leukemia
  • Monoclonal Antibody
  • Therapy
  • Daiichi Sankyo Company
  • PRODUCTS UNDER DEVELOPMENT BY COMPANIES, H2 2016 (CONTD..6)
  • myelofibrosis or myeloproliferative neoplasm (MPN)/ myelodysplastic syndrome (MDS). The trial was registered with the U.S. National Institutes of Health.

No grade ## gastrointestinal adverse events were reported.

  • Hospital
  • In Vitro Diagnostic Reagent
  • Leukemia
  • Lung Cancer
  • AB Science SA
  • PRODUCTS UNDER DEVELOPMENT BY COMPANIES, H1 2017
  • KARYOPHARM THERAPEUTICS INC

We anticipate that this regimen will continue to show reduced rates of cytopenias, neuropathy and gastrointestinal side effects based on the continuing STOMP results.

  • Leukemia
  • Lymphoma
  • United States
  • World
  • Karyopharm Therapeutics Inc.